Denifanstat
Based on 8 publication(s) in Google Scholar
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.58%
- CAS No.: 1399177-37-7
- Formule: C27H29N5O
- Masse moléculaire:439.55
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Lipid Metabolism Compound Library
HY-L091
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Denifanstat
More- Cancer Cell. 2026 Feb 9;44(2):383-404.e18. [Abstract]
- Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]
- Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]
- J Adv Res. 2025 Aug 8:S2090-1232(25)00596-X. [Abstract]
- Cell Death Dis. 2026 Jun 3. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120890. [Abstract]
- bioRxiv. 2026 Feb 1.
- bioRxiv. 2024 August 23.
Customer Validation & Images
-
In Vivo Efficacy Study
-
IF
-
IF
-
In Vivo Efficacy Study
-
RT-PCR
Activité biologique
IC50: 0.052 μM (FASN)[1]
Denifanstat (compound 152) is a potent FASN inhibitor[2].
Fatty Acid Synthase (FASN) inhibition prevents palmitoylation of SARS-CoV2 spike protein[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1399177-37-7
-
Appearance Solid
-
Masse moléculaire 439.55
-
Formule C27H29N5O
-
Color White to off-white
-
SMILES
N#CC1=CC=C(C2CCN(C(C3=CC(C4=NC(C)=NN4)=C(C5CCC5)C=C3C)=O)CC2)C=C1
-
Synonyms
TVB-2640; FASN-IN-2; ASC-40
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. [Abstract]2026 Feb 9;44(2):383-404.e18. PMID: 41544627 -
Cancer Commun (Lond)
Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. [Abstract]2025 Aug;45(8):1010-1037. PMID: 40439109
Denifanstat purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]
Denifanstat (10 mg/kg; i.g.; every day; from day7 to day20); Lovastatin(10 mg/kg; i.g.; every day; from day7 to day20); Simvastatin (50 mg/kg; i.g.; every day; from day7 to day20). Tumor growth curve of each group (4 mice/group). ns, not significant; * P < 0.05, **P < 0.01, ***P < 0.001.
-
Nat Metab
2021 Nov;3(11):1466-1475. PMID: 34580494
Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]
Fatty acid synthase inhibitors suppress SARS-CoV-2 virus replication. Representative fluorescence images of SARS-CoV-2-mNG infected multiple cell lines. Indicated cells were pre-treated with Denifanstat (TVB-2640) (1-2 µM) at the following concentration: NCI-H1355 and NCI-1437 (2 µM); Caco-2 (2 µM); MEF-hACE2 (1 µM), from 16 h before infection and then infected with SARS-CoV-2-mNG at an MOI = 0.1(NCI-H1355, NCI-1437), MOI = 0.05 (Caco-2), MOI = 0.01 (MEF-hACE2). Fluorescence images were acquired at 48 hpi. Hoechst 33342 was used for nuclear staining. Scale bar: 200 μm.
Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]
Palmitic acid reverses the effects of knockout and inhibition of fatty acid synthase on viral replication. Representative fluorescence images of palmitoylated protein assay. HEK293T-hACE2 and NCI-H1355 cells were treated with Denifanstat (TVB-2640)100 nM; NCI-H1355 cells: Denifanstat (TVB-2640) 2 µM for 24 h and the EZClick palmitic acid label was added to the medium for another 24 h. Cells were then processed and analyzed by microscopy following the manufacturer's instruction. Scale bar: 40 μm.
Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]
Denifanstat (TVB-2640) reduces body weight loss and prolongs mouse survival after SARS-CoV-2 infection. K18-hACE2 transgenic mice were infected with SARS-CoV-2 virus and i.p. injected with TVB-2640 (8 mg/kg; i.p.; from day 0 to day 5.
Denifanstat purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Nov;3(11):1466-1475. [Abstract]
Fatty acid synthase inhibitors suppress the replication of SARS-CoV-2 variants. NCI-H1355 cells were pre-treated with Denifanstat (TVB-2640) (2 µM) for 16 h and infected with SARS-CoV-2 variants with an MOI of 0.1. The cells were analyzed by qPCR for viral RNA at 48 hpi.
-
J Adv Res
Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma. [Abstract]2025 Aug 8:S2090-1232(25)00596-X. PMID: 40784518 -
Cell Death Dis
The OAS1-FASN axis promotes pancreatic cancer by coordinating lipogenic stress and the unfolded protein response. [Abstract]2026 Jun 3. PMID: 42236684 -
J Ethnopharmacol
Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]2026 Feb 28:357:120890. PMID: 41232632 -
-
Solvant et solubilité
DMSO : 100 mg/mL (227.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2751 mL | 11.3753 mL | 22.7505 mL | 56.8764 mL |
| 5 mM | 0.4550 mL | 2.2751 mL | 4.5501 mL | 11.3753 mL | |
| 10 mM | 0.2275 mL | 1.1375 mL | 2.2751 mL | 5.6876 mL | |
| 15 mM | 0.1517 mL | 0.7584 mL | 1.5167 mL | 3.7918 mL | |
| 20 mM | 0.1138 mL | 0.5688 mL | 1.1375 mL | 2.8438 mL | |
| 25 mM | 0.0910 mL | 0.4550 mL | 0.9100 mL | 2.2751 mL | |
| 30 mM | 0.0758 mL | 0.3792 mL | 0.7584 mL | 1.8959 mL | |
| 40 mM | 0.0569 mL | 0.2844 mL | 0.5688 mL | 1.4219 mL | |
| 50 mM | 0.0455 mL | 0.2275 mL | 0.4550 mL | 1.1375 mL | |
| 60 mM | 0.0379 mL | 0.1896 mL | 0.3792 mL | 0.9479 mL | |
| 80 mM | 0.0284 mL | 0.1422 mL | 0.2844 mL | 0.7110 mL | |
| 100 mM | 0.0228 mL | 0.1138 mL | 0.2275 mL | 0.5688 mL |
Denifanstat Related Classifications
HY-112829 Related Classifications
Powered by Bioz